| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Experimental Therapeutics, Preclinical Pharmacology |
Division of Hematology and Oncology, Cedars-Sinai Medical Center, Los Angeles, California 90048 [M. H. M., H. H. Y., K. P., S. M., J. M. F., C. A., M. J. B., M. F., E. R., J. N., A. M., N. S-S., R. A. V., J. R. B.]; University of California Los Angeles School of Medicine and Jonsson Comprehensive Cancer Center, Los Angeles, California [M. H. M., H. H. Y., K. P., S. M., J. M. F., C. A., M. J. B., M. F., E. R., J. N., A. M., N. S-S., R. A. V., J. R. B.]; Division of Microbiology, University of California San Diego School of Medicine, San Diego, California [Z-q. W.]; and Millennium Pharmaceuticals, Inc., Cambridge, Massachusetts [J. A.]
 |
ABSTRACT |
|---|
 Top ABSTRACT INTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
B (NF-B) activity is associated with increased tumor cell survival in multiple myeloma. The function of NF-B is inhibited through binding to its inhibitor, IB. Release of activated NF-B follows proteasome-mediated degradation of IB resulting from phosphorylation of the inhibitor and, finally, conjugation with ubiquitin. We report that myeloma cells have enhanced IB
phosphorylation and increased NF-B activity compared with normal hematopoietic cells. The proteasome inhibitor PS-341 blocked nuclear translocation of NF-B, blocked NF-B DNA binding, and demonstrated consistent antitumor activity against chemoresistant and chemosensitive myeloma cells. The sensitivity of chemoresistant myeloma cells to chemotherapeutic agents was markedly increased (100,000–1,000,000-fold) when combined with a noncytotoxic dose of PS-341 without affecting normal hematopoietic cells. Similar effects were observed using a dominant negative super-repressor for IB. Thus, these results suggest that inhibition of NF-B with PS-341 may overcome chemoresistance and allow doses of chemotherapeutic agents to be markedly reduced with antitumor effects without significant toxicity. |
INTRODUCTION |
|---|
|
TopABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
Members of the NF-B transcription factor family may play an important role in the pathogenesis of lymphoid malignancies (4, 5, 6, 7, 8)
. The formation of a heterodimer between subunits p50 and p65 is the most common NF-B complex (9
, 10)
. In unstimulated cells, NF-B complexes are associated with a class of inhibitory proteins, called IB. NF-B is bound to IB in the cytoplasm and the transcription factor is thereby rendered inactive. The family of inhibitor proteins includes IB, IBß, IB
, and the putative proto-oncogene product bcl-3 (11)
. NF-B activation generally requires signal-induced degradation of IB, thus releasing the NF-B transcription factor so that it can translocate to the nucleus (12, 13, 14)
. The IB proteins contain multiple ankyrin repeats and physically associate with NF-B proteins. Signal-induced activation of NF-B is preceded by phosphorylation and degradation of IB (15, 16, 17, 18)
through the ubiquitin-proteasome pathway (19)
. NF-B is involved in the control of various cellular processes, such as immune and inflammatory responses, cell growth, bone resorption, and apoptosis. Importantly, NF-B activation increases the survival of tumor cells and confers their resistance to chemotherapy (20, 21, 22, 23)
. Elevated levels of NF-B activity were found in relapsing MM (24)
, suggesting that this transcription factor could be used as a prognostic marker as well as a target for therapy to prevent progression of the disease.
Newly developed proteasome inhibitors, such as PS-341 (Millennium Inc., Boston, MA), suppress NF-B activity by inhibiting IB degradation (25, 26, 27)
. The inhibition of NF-B activity by this proteasome inhibitor correlated with antitumor activity against human prostate cancer and Burkitt’s lymphoma in murine models (26
, 27)
. However, it would be an oversimplification to attribute all of the antitumor effects of PS-341 to the inhibition of NF-B activity. PS-341 has been shown to affect many intracellular regulatory molecules such as p53 and cyclin-dependent kinase inhibitors p21 and p27 (25)
. PS-341 can also block the antiapoptotic effects of Bcl-2, even though the antiapoptotic effects of Bcl-2 are independent of NF-B activity. PS-341 induced apoptosis of human IgA (ARP-1) myeloma cells that overexpressed Bcl-2 protein in a dose-dependent fashion (28)
. PS-341 can also decrease the binding of MM cells to BM stromal cells, and we know that the interaction between MM cells and BM stromal cells through extracellular molecules plays an important role in the survival of MM cells (29)
. PS-341 has shown growth-inhibitory effects in Lewis lung carcinoma treated with doxorubicin, 5-fluorouracil, cisplatin, and paclitaxel (27)
. This drug also demonstrated antiangiogenic effects in an orthotopic pancreatic cancer model (32)
. PS-341 has shown anti-MM activity in vitro(29)
. Importantly, a Phase I clinical trial evaluating single-agent PS-341 for patients with chemoresistant MM showed antitumor responses (31)
. In addition, early results from an ongoing Phase II clinical trial show evidence of antitumor activity in relapsing MM patients (32)
. We investigated the relationship between the level of NF-B activity and the sensitivity of MM cells to cytotoxic agents and whether the proteasome inhibitor PS-341 would suppress the growth of MM cells and sensitize them to treatment with cytotoxic agents.
|
MATERIALS AND METHODS |
|---|
|
TopABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
BM aspirates and PB specimens were collected in heparinized tubes and then diluted 1:1 with Leibovitz L-15 medium (Life Technologies, Inc., Grand Island, NY) supplemented with fetal bovine serum (Life Technologies, Inc.). The mononuclear cell fraction was enriched by Ficoll-Hypaque (Pharmacia, Uppsala, Sweden) density gradient sedimentation at 600 x g for 20 min and washed twice in L-15/fetal bovine serum media. The percentage of tumor cells in fresh BM samples was determined by microscopic examination along with immunohistochemistry showing light chain restriction.
CD34-expressing cells were selected from healthy individuals’ (donors for patients undergoing allogeneic transplantation) BMMCs using the Miltenyi column (Miltenyi Biotec, Auburn, CA). BMMCs were placed on the Miltenyi column and washed with Miltenyi washing buffer. The CD34-expressing cells were harvested by washing the column with Miltenyi elution buffer, and the harvested cells contained 80–95% CD34-expressing cells.
BMMCs, PBMCs, and MM cell lines were suspended in 10 ml of RPMI medium (Irvine Scientific, Santa Ana, CA) supplemented with 10% FCS (Gemini Bio-products, Calabasas, CA), penicillin (100 units/ml; Irvine Scientific), and streptomycin (100 mg/ml; Irvine Scientific) in 75-cm flasks (Costar, Cambridge, MA). Cells were incubated at 37°C in a CO2 incubator.
Nuclear and Cytosolic Extract Preparation.
Nuclear and cytosolic extracts were prepared according to the method of Schreiber et al. (33)
, with modifications. Briefly, cell pellets were suspended in buffer A [10 mM HEPES (pH 7.9), 10 mM KCl, 1 mM EDTA, 1 mM DTT, 1x Complete (Boehringer Mannheim), and 0.5% NP40 (Fluka, Milwaukee, WI)] and incubated on ice for 15 min followed by centrifugation at 12,000 rpm for 5 min at 4°C. The supernatant that contained cytosolic protein was separated and stored at -80°C. The pellet was resuspended with buffer B [20 mM HEPES (pH 7.9), 0.4 M NaCl, 1 mM EDTA, 1 mM DTT, and 1x Complete], kept on ice for 30 min, and spun down at 12,000 rpm for 5 min at 4°C. The supernatants containing nuclear protein were stored at -80°C. The protein concentrations were determined with the Bradford method (Bio-Rad Laboratories).
EMSA.
The sequence (5'-3') of the oligonucleotide is derived from the NF-B binding sequence from the promoter region of TNF-. The oligonucleotide was end-labeled with [32P]CTP and purified through G-25 columns. Ten µg of nuclear extracts from MM cell lines and fresh BM aspirates from either MM patients or healthy subjects were mixed with the radiolabeled NF-B oligonucleotide (5–20 x 104 cpm) in binding buffer containing 4% glycerol, 1 mM MgCl2, 0.5 mM EDTA, 0.5 mM DTT, 50 mM NaCl, and 10 mM Tris-HCl at pH 7.5. The reaction mixtures were incubated for 20 min at room temperature followed by electrophoresis on a 4% nondenaturing polyacrylamide gel.
Fluorescence Assay for Intracellular Presence of NF-B.
The relative amounts of nuclear and cytoplasmic NF-B were evaluated using the NF-B HitKit (Cellomics, Inc., Pittsburgh, PA). Using a 96-well plate, 5000 cells/well were incubated for at least 4 h. Next, culture medium was aspirated and replaced with 200 µl/well prewarmed fixation solution. The cells were incubated at room temperature for 10 min, and the fixation solution was replaced with permeabilization buffer. After washing the plate with 200 µl/well washing buffer, 50 µl of primary antibody solution were added into each well, followed by incubation for 1 h at room temperature. Next, 50 µl of staining solution were added to each well and also incubated for 1 h. The cells were incubated with 200 µl of detergent buffer for 10 min, which was replaced with 200 µl of washing buffer. The cells were evaluated using an UV light microscope.
Western Blot Analysis.
Phosphorylation of IB was analyzed using the PhosphoPlus IB kit (Cell Signaling, Beverly, MA). Cytosol proteins were run on a 10% polyacrylamide gel and then transferred to polyvinylidene difluoride membrane and hybridized with anti-IB Ser-32 and anti-IB antibodies. Western blots were developed using an electrochemiluminescence reagent kit (Kirkegard & Perry Laboratories). The intensity of protein bands was measured by autoradiography.
Cell Proliferation Test (MTT Assay).
Cells were cultured in T25 flasks at 37°C. After starvation overnight, cells were placed in 96-well plates in fresh medium with cytotoxic agents (Becton Dickinson Labware, Franklin Lakes, NJ). MTT reagent (Sigma, St. Louis, MO) was added to each well after 48 h. The absorbance of samples was determined using a microtiter plate (ELISA) reader at a wavelength of 575 nm. The reference wavelength was 650 nm.
Apoptosis Assay.
Apoptosis was determined by using the annexin V-EGFP kit (Clontech, Palo Alto, CA) or the cell death detection ELISA plus kit (Roche, Mannheim, Germany). Cells (1 x 105) were either treated with PS-341 or transduced by dominant negative IB. For the annexin V-EGFP kit, cells were incubated with 5 µl of annexin V and 10 µl of propidium iodide for 15 min and then evaluated by flow cytometry. For the cell death detection ELISA plus kit, 1 x 104 cells were lysed with 200 µl of lysis buffer. Cell lysates were placed on streptavidin-coated multiwell plates and incubated with immunoreagent for 2 h. Plates were read using a mQuant plate reader for photometric analysis.
Adenovirus Transfections with Dominant Negative IB.
Recombinant replication-deficient adenoviruses containing dominant negative IB, which were kindly supplied by Dr. Richard Gaynor (University of Texas Southwestern Medical School, Dallas, TX), were used to infect 5 x 105 MM cells (ARH77 and U266/LR7) in serum-free medium at a ratio of 10,000 viral particles/cell for 72 h. The viral titers were determined based on the percentage of NIH3T3 cells infected after exposure to freshly collected virus. Adenovirus containing the transfection vector without the IB gene was used as negative control. After incubation, cells were washed with serum-free medium, followed by quantitative measurement of apoptosis by ELISA or annexin V assay.
|
RESULTS |
|---|
|
TopABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
B Is Elevated in MM Cells.B activity, we obtained nuclear extracts from chemoresistant and chemosensitive MM cell lines and fresh BMMCs from MM patients (n = 4) with a high proportion of tumor cells (80–95%). These extracts were incubated with [32P]CTP-labeled oligonucleotide probes containing a NF-B-binding sequence derived from the promoter region of the TNF- gene. We used the nuclear proteins from BMMCs from healthy individuals as controls. The activity of NF-B was elevated in both chemoresistant and chemosensitive cell lines as well as in fresh BMMCs from MM patients when compared with normal BMMCs (Fig. 1)
. Moreover, among four MM cell lines, the density of the DNA-binding band showed that the NF-B activity was approximately 3 times higher in the U266/dox chemoresistant MM cell line than in the U266 chemosensitive MM cell line. However, no difference in NF-B activity was found between RPMI8226 and RPMI8226/dox4 MM cell lines.
|
B protein levels. Cytosol protein extracts were obtained at 1, 2, 3, 4, and 5 h after doxorubicin treatment of the U266 cell line with low concentrations (4 x 10-9 M) of doxorubicin, which corresponds to approximately one-tenth of the serum concentration measured in patients who receive standard doses of this agent. First, the amount of IB phosphorylation, as determined by an antibody recognizing phosphorylated IB, increased after exposure to doxorubicin (Fig. 2)
. Second, as measured by a Western blot assay, the level of cytoplasmic IB protein decreased after exposure to this drug (data not shown).
|
B DNA Binding and Causes Cytotoxicity of MM Cell Lines.B is mediated by the proteasome, inhibiting its function should increase IB levels, thus inhibiting NF-B activity. We examined the effects of the proteasome inhibitor PS-341 (500 pg/ml to 500 ng/ml) on the growth of MM cell lines using the MTT assay. The growth of chemosensitive (U266, ARH77, RPMI8226, and WAD-1) and chemoresistant (U266/LR7, U266/dox4, and RPMI8226/LR5) MM cell lines was substantially inhibited by PS-341 (Fig. 3)
with an IC50 of 10–40 ng/ml. Interestingly, all chemoresistant cell lines demonstrated a right shift in their dose-response curves, indicating that these chemoresistant cell lines were more sensitive to treatment with PS-341 than chemosensitive lines, consistent with their enhanced NF-B activity. We determined whether treatment with PS-341 decreased NF-B DNA binding activity using the EMSA and fluorescence assay. After 10 h of treatment with 10 ng/ml PS-341 (a dose that is relatively equivalent to those used in the clinical patients), we performed EMSA on nuclear protein extracts from MM cell lines (U266/dox4, RPMI8226/dox4, U266/LR7, and RPMI8226/LR5), and we also tested the intracellular location of NF-B in ARH77 cells using a fluorescence-based antibody assay. After treatment with PS-341, the vast majority of NF-B was contained in the cytoplasm, where it cannot function as a transcription factor, whereas most of the protein complex is located in the nucleus in the absence of the proteasome inhibitor (Fig. 4A)
. We also evaluated the DNA binding capacity of NF-B in MM cell lines after exposure to PS-341. PS-341 markedly decreased NF-B DNA binding activity in a variety of chemosensitive and chemoresistant cell lines (Fig. 4B)
.
|
|
B Produced Apoptosis in MM Cells.B activity as a potential therapeutic target in MM, we transduced two MM cell lines (ARH77 and the melphalan-resistant U266/LR7) with an adenovirus vector carrying an inhibitor of NF-B activity, a dominant negative IB. This super-repressor of IB (dm IB) has alterations at amino acid positions 32 and 36 (from serine to alanine) and is resistant to phosphorylation, resulting in increased cellular levels of IB. With increased amounts of cellular IB bound to NF-B, the activity of NF-B will be suppressed. The cell lines were exposed to recombined adenovirus with the super-repressor form (dm IB) for 2 h and analyzed using both the annexin V apoptosis assay and photometric ELISA. ARH77 and U266/LR7 cell lines infected with the adenovirus control vector (without the IB gene) were used as negative controls. Compared with the negative controls, apoptosis was increased by approximately 13 and 8 fold in the U266/LR7 and ARH77 cells transfected with dm IB, respectively (Fig. 5)
. These results support the concept that increasing cellular levels of IB (which also results with PS-341 treatment) is a potential means of producing cytotoxicity in chemosensitive as well as chemoresistant MM.
|
). In contrast, when the resistant MM cell lines were exposed to melphalan with PS-341, these cell lines became extremely sensitive to melphalan at a concentration of 3 x 10-11 M, which is 1,000,000-fold lower than the concentration necessary for melphalan alone to induce cytotoxicity. Similar effects were observed between PS-341 and doxorubicin or mitoxantrone, with PS-341 increasing the sensitivity of the doxorubicin-resistant and mitoxantrone-resistant MM cell lines by 100,000-fold each (Fig. 6B)
. Similar synergistic effects were also found in the treatment with the same combinations in fresh BM samples obtained from active patients with MM (Fig. 6C)
.
|
. There was a marked increase in apoptosis induced by PS-341 and melphalan compared with melphalan alone, which correlated with the results of the MTT assay.
To determine the effects of PS-341 on other tumor types, we treated the T-cell leukemia cell line NB-4, human myeloid leukemia cell line U937, B-cell leukemia cell line molt-4, primary effusion lymphoma cell line KS-1, and kidney tumor cell line 293 with PS-341 alone or in combination with chemotherapeutic agents. Similar experiments were also performed on normal unstimulated and stimulated (with 20 nM phytohemagglutinin for 30 min) PBMCs and CD34-selected BMMCs obtained from healthy individuals. Suppression of proliferation in either these non-MM cell lines or normal hematopoietic cells was found with PS-341 treatment at higher concentrations (IC50, 100–300 ng/ml) than in the MM cell lines (IC50, 10-40 ng/ml; data not shown). When added to chemotherapy, PS-341 showed very little synergism in inhibiting the proliferation of these non-MM cell lines or normal CD34-selected BMMCs or PBMCs (Fig. 6E)
.
|
DISCUSSION |
|---|
|
TopABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
B in response to chemotherapy is a principal mechanism of tumor chemoresistance. Inhibition of such inducible NF-B activation enhances apoptosis. Increased activity of NF-B proteins has been reported in solid tumors resistant to chemotherapy (36)
. In this report, we found that the activity of NF-B was elevated in MM tumor cells. The activity of NF-B appeared to be higher in chemoresistant MM cell lines compared with chemosensitive ones, although the difference was not always consistent between chemosensitive versus chemoresistant MM cells (Fig. 1)
. Further work is needed to clarify this. The level of IB phosphorylation was significantly higher, and amounts of this inhibitor were reduced in MM cells after exposure to chemotherapeutic agents. These results suggest that increases in NF-B activity may help MM cells evade chemotherapy-induced cytotoxicity.
Phosphorylated IB becomes ubiquitinated and then becomes degraded through the proteasome pathway, resulting in release of activated NF-B. The blockage of this degradation by proteasome inhibitors such as PS-341 increases the level of IB, resulting in the inhibition of the function of NF-B. In this report, PS-341 was shown to markedly reduce nuclear localization of this transcription factor and its DNA binding activity and markedly suppress growth of tumor cells from MM patients and cell lines. Among the MM cell lines analyzed, the chemoresistant lines were more sensitive to treatment with PS-341 than the chemosensitive lines.
The use of other combinations of treatment for cancer patients has been shown to be more efficacious than single-agent therapy (37, 38, 39, 40)
. In MM patients, the addition of GCs to chemotherapy (melphalan) improves overall survival (41)
. Part of the efficacy of this combination may result from the effects of GCs on NF-B activity. It has recently been shown that GCs interfere with the interaction of one of the NF-B members, p65, with the basal transcription machinery (42)
. This inhibition of NF-B function by GCs may lead to the sensitization of MM cells to the cytotoxic effects of chemotherapy, similar to what we have shown in this study with PS-341. By combining a noncytotoxic PS-341 dose with the chemotherapeutic agents melphalan, doxorubicin, or mitoxantrone, we overcame drug resistance in highly chemoresistant MM cell lines. These cell lines became sensitive to chemotherapeutic agents at markedly lower concentrations (100,000–1,000,000-fold) than were necessary to kill these cells without PS-341. Both increased apoptosis and a reduction in tumor cell accumulation result from exposure of MM cells to chemotherapeutic agents with the addition of PS-341. In contrast, we did not find any significant cytotoxic effect of the proteasome inhibitor alone or in combination with chemotherapy, except at very high doses in normal samples (CD34-selected BMMCs and PBMCs) that were obtained from healthy individuals and cell lines derived from other types of tumors. These results suggest that the antitumor effects of PS-341 alone and its enhancement of chemotherapy cytotoxicity have differential effects on MM cells than on normal hematopoietic stem and PB cells.
To provide further support for the importance of inhibiting NF-B as an effective therapy for MM, we performed studies on MM cells that were infected with dominant negative IB, and we showed a similar apoptosis-enhancing effect. These data provide further support for inhibiting NF-B activity as a new strategy for the treatment of MM. Although these results suggest that proteasome inhibitors and other agents that increase IB levels may overcome chemoresistance by inhibiting NF-B activity in MM cells, it is still possible that other factors may contribute to this effect. In fact, recent studies show that another inhibitor of IB, Bay 11-7085, actually produces its antileukemic effects through a p38 mitogen-activated protein kinase-dependent but NF-B-independent mechanism (43)
. In addition, drug resistance to camptothecins may result from proteasome-mediated degradation of topoisomerase I rather than IB (44)
. It also remains to be determined what leads to the increased NF-B activity in MM cells. Recent studies from our laboratory and others suggest that polymorphisms and/or mutations of the IB gene might reduce the function and/or levels of this inhibitor among patients with MM and other B-cell malignancies (45)
. Abnormalities in other parts of the signal transduction pathway may also be present in MM patients’ tumor cells, such as alterations in the IB kinase complex or tumor necrosis receptor-associated factors.
Our findings indicate that resistance to chemotherapy in MM may be related to overactivity of NF-B. By using the proteasome inhibitor PS-341, which reduces NF-B activity, chemoresistance in MM cells can be overcome without significant effects on normal hematopoietic cells. Combining PS-341 with chemotherapeutic reagents markedly reduces the concentrations of these drugs that are cytotoxic without affecting normal hematopoietic cells. Thus, these results should provide the basis for clinical trials using drug combinations involving much lower doses of chemotherapy with inhibitors of NF-B activity that should produce maximal anti-MM activity with minimal toxicity.
|
|
ACKNOWLEDGMENTS |
|---|
B vector, Drs. James Economou and Anthony Ribas for giving us the adenovirus negative control vector, and Christine James for assistance in editing and typing the manuscript. |
FOOTNOTES |
|---|
1 Supported by the Lymphoma Research Foundation, Myeloma Research Fund, and the International Myeloma Foundation. 
2 To whom requests for reprints should be addressed, at Division of Hematology and Oncology, Cedars-Sinai Medical Center, 8700 Beverly Boulevard, Room 5416, Los Angeles, CA 90048. Phone: (310) 423-5093; Fax: (310) 423-1977; E-mail: berensonj{at}cshs.org
3 The abbreviations used are: MM, multiple myeloma; NF-B, nuclear factor B; BM, bone marrow; BMMC, bone marrow mononuclear cell; PB, peripheral blood; PBMC, peripheral blood mononuclear cell; EMSA, electrophoretic mobility shift assay; TNF, tumor necrosis factor; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; GC, glucocorticosteroid.
Received 4/22/02; revised 10/18/02; accepted 10/22/02.
|
REFERENCES |
|---|
|
TopABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
B/IB proteins and cancer. Oncogene, 13: 1367-1378, 1996.[Medline]
B gene in Hodgkin’s disease suggest a tumour suppressor role for IB. Oncogene, 18: 3063-3070, 1999.[CrossRef][Medline]
B is a characteristic feature of mycosis fungoides: implications for apoptosis resistance and pathogenesis. Hum. Pathol., 31: 1482-1490, 2000.[CrossRef][Medline]
B. Immunol. Today, 19: 80-88, 1998.[CrossRef][Medline]
B transcription factors. Oncogene, 18: 6910-6924, 1999.[CrossRef][Medline]
B proteins: structure, function and regulation. Semin. Cancer Biol., 8: 75-82, 1997.[CrossRef][Medline]
B: ten years after. Cell, 87: 13-20, 1996.[CrossRef][Medline]
B. Int. J. Biochem. Cell Biol., 27: 865-879, 1995.[CrossRef][Medline]
B/Rel transcription factors. Microbiol. Rev., 59: 481-505, 1995.B proteins: multifunctional regulators of Rel/NF-B transcription factors. Genes Dev., 7: 2064-2070, 1993.B and its inhibitor, IB. Proc. Natl. Acad. Sci. USA, 90: 2532-2536, 1993.B is necessary for activation of transcription factor NF-B. Nature (Lond.), 365: 182-185, 1993.[CrossRef][Medline]
B) and enhanced processing of the NF-B precursor p105 are obligatory steps in the activation of NF-B. Nucleic Acids Res., 21: 5059-5066, 1993.B1 precursor protein and the activation of NF-B. Cell, 78: 773-785, 1994.[CrossRef][Medline]
B activation is related to the resistance of lung cancer cells to TNF--induced apoptosis. Biochem. Biophys. Res. Commun., 273: 140-146, 2000.[CrossRef][Medline]
B/IB signaling pathway may contribute to the mediation of paclitaxel-induced apoptosis in solid tumor cells. Cancer Res., 60: 4426-4432, 2000.B. Cancer Res., 60: 6557-6562, 2000.B in the rescue of multiple myeloma cells from glucocorticoid-induced apoptosis by bcl-2. Blood, 93: 3044-3052, 1999.B. Nat. Med., 5: 412-417, 1999.[CrossRef][Medline]
B-dependent mechanism. Mol. Pharmacol., 56: 797-806, 1999.B inhibition. Cancer Res., 61: 3535-3540, 2001.B inhibitor causes leukemia cell death through a p38 MAP kinase-dependent. NF-B-independent mechanism. Cancer Res., 61: 6290-6296, 2001.B gene associated with an increased risk of multiple myeloma. Cancer Genet. Cytogenet., in press, 2003.This article has been cited by other articles:
|
|
 |
|
  B. Sung, A. B. Kunnumakkara, G. Sethi, P. Anand, S. Guha, and B. B. Aggarwal Curcumin circumvents chemoresistance in vitro and potentiates the effect of thalidomide and bortezomib against human multiple myeloma in nude mice model Mol. Cancer Ther., April 1, 2009; 8(4): 959 - 970. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. R. Berenson, O. Yellin, R. Patel, H. Duvivier, Y. Nassir, R. Mapes, C. D. Abaya, and R. A. Swift A Phase I Study of Samarium Lexidronam/Bortezomib Combination Therapy for the Treatment of Relapsed or Refractory Multiple Myeloma Clin. Cancer Res., February 1, 2009; 15(3): 1069 - 1075. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Bisping, D. Wenning, M. Kropff, D. Gustavus, C. Muller-Tidow, M. Stelljes, G. Munzert, F. Hilberg, G. J. Roth, M. Stefanic, et al. Bortezomib, Dexamethasone, and Fibroblast Growth Factor Receptor 3-Specific Tyrosine Kinase Inhibitor in t(4;14) Myeloma Clin. Cancer Res., January 15, 2009; 15(2): 520 - 531. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. G. Richardson, C. Mitsiades, J. Laubach, D. Chauhan, T. Hideshima, and K. Anderson Realizing the Anticancer Potential of Proteasome Inhibition: The Clinical Development of Bortezomib and Second-generation Proteasome Inhibitors ASCO Educational Book, January 1, 2009; 2009(1): 163 - 170. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Chanan-Khan, P. Sonneveld, M. W. Schuster, E. A. Stadtmauer, T. Facon, J.-L. Harousseau, D. Ben-Yehuda, S. Lonial, H. Goldschmidt, D. Reece, et al. Analysis of Herpes Zoster Events Among Bortezomib-Treated Patients in the Phase III APEX Study J. Clin. Oncol., October 10, 2008; 26(29): 4784 - 4790. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. F. San Miguel, R. Schlag, N. K. Khuageva, M. A. Dimopoulos, O. Shpilberg, M. Kropff, I. Spicka, M. T. Petrucci, A. Palumbo, O. S. Samoilova, et al. Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma N. Engl. J. Med., August 28, 2008; 359(9): 906 - 917. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Gu, X. Chen, G. Gao, and H. Dong Caspase-2 functions upstream of mitochondria in endoplasmic reticulum stress-induced apoptosis by bortezomib in human myeloma cells Mol. Cancer Ther., August 1, 2008; 7(8): 2298 - 2307. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. M Voorhees, E C. Dees, B. O'Neil, and R. Z Orlowski The Proteasome as a Target for Cancer Therapy Am. Assoc. Cancer Res. Educ. Book, April 12, 2008; 2008(1): 153 - 170. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Z. Orlowski and D. J. Kuhn Proteasome Inhibitors in Cancer Therapy: Lessons from the First Decade Clin. Cancer Res., March 15, 2008; 14(6): 1649 - 1657. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Shi, G. J. Tricot, T. K. Garg, P. A. Malaviarachchi, S. M. Szmania, R. E. Kellum, B. Storrie, A. Mulder, J. D. Shaughnessy Jr, B. Barlogie, et al. Bortezomib down-regulates the cell-surface expression of HLA class I and enhances natural killer cell-mediated lysis of myeloma Blood, February 1, 2008; 111(3): 1309 - 1317. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Colado, S. Alvarez-Fernandez, P. Maiso, J. Martin-Sanchez, M. B. Vidriales, M. Garayoa, E. M. Ocio, J. C. Montero, A. Pandiella, and J. F. San Miguel The effect of the proteasome inhibitor bortezomib on acute myeloid leukemia cells and drug resistance associated with the CD34+ immature phenotype Haematologica, January 1, 2008; 93(1): 57 - 66. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. H.D. Hallett, E. Ames, M. Motarjemi, I. Barao, A. Shanker, D. L. Tamang, T. J. Sayers, D. Hudig, and W. J. Murphy Sensitization of Tumor Cells to NK Cell-Mediated Killing by Proteasome Inhibition J. Immunol., January 1, 2008; 180(1): 163 - 170. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C.-K. Min, M.-J. Lee, K.-S. Eom, S. Lee, J.-W. Lee, W.-S. Min, C.-C. Kim, M. Kim, J. Lim, Y. Kim, et al. Bortezomib in Combination with Conventional Chemotherapeutic Agents for Multiple Myeloma Compared with Bortezomib Alone Jpn. J. Clin. Oncol., December 21, 2007; (2007) hym126v1. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. J. Kuhn, Q. Chen, P. M. Voorhees, J. S. Strader, K. D. Shenk, C. M. Sun, S. D. Demo, M. K. Bennett, F. W. B. van Leeuwen, A. A. Chanan-Khan, et al. Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma Blood, November 1, 2007; 110(9): 3281 - 3290. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Z. Orlowski, A. Nagler, P. Sonneveld, J. Blade, R. Hajek, A. Spencer, J. San Miguel, T. Robak, A. Dmoszynska, N. Horvath, et al. Randomized Phase III Study of Pegylated Liposomal Doxorubicin Plus Bortezomib Compared With Bortezomib Alone in Relapsed or Refractory Multiple Myeloma: Combination Therapy Improves Time to Progression J. Clin. Oncol., September 1, 2007; 25(25): 3892 - 3901. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. E. Davies, P. Wu, M. Jenner, M. Srikanth, R. Saso, and G. J. Morgan The combination of cyclophosphamide, velcade and dexamethasone (CVD) induces high response rates with comparable toxicity to velcade alone (V) and velcade plus dexamethasone (VD) Haematologica, August 1, 2007; 92(8): 1149 - 1150. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Manochakian, K. C. Miller, and A. A. Chanan-Khan Clinical Impact of Bortezomib in Frontline Regimens for Patients with Multiple Myeloma Oncologist, August 1, 2007; 12(8): 978 - 990. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Chen, M. S. Gordon, R. A. Campbell, M. Li, C. S. Wang, H. J. Lee, E. Sanchez, S. J. Manyak, D. Gui, D. Shalitin, et al. Pleiotrophin is highly expressed by myeloma cells and promotes myeloma tumor growth Blood, July 1, 2007; 110(1): 287 - 295. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. G. Richardson, C. Mitsiades, R. Schlossman, N. Munshi, and K. Anderson New Drugs for Myeloma Oncologist, June 1, 2007; 12(6): 664 - 689. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Palumbo, M. T. Ambrosini, G. Benevolo, P. Pregno, N. Pescosta, V. Callea, C. Cangialosi, T. Caravita, F. Morabito, P. Musto, et al. Bortezomib, melphalan, prednisone, and thalidomide for relapsed multiple myeloma Blood, April 1, 2007; 109(7): 2767 - 2772. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. R. Berenson, J. Matous, R. A. Swift, R. Mapes, B. Morrison, and H. S. Yeh A Phase I/II Study of Arsenic Trioxide/Bortezomib/Ascorbic Acid Combination Therapy for the Treatment of Relapsed or Refractory Multiple Myeloma Clin. Cancer Res., March 15, 2007; 13(6): 1762 - 1768. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Dreicer, D. Petrylak, D. Agus, I. Webb, and B. Roth Phase I/II Study of Bortezomib Plus Docetaxel in Patients with Advanced Androgen-Independent Prostate Cancer Clin. Cancer Res., February 15, 2007; 13(4): 1208 - 1215. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Williamson, J. L. Blank, F. J. Bruzzese, Y. Cao, J. S. Daniels, L. R. Dick, J. Labutti, A. M. Mazzola, A. D. Patil, C. L. Reimer, et al. Comparison of biochemical and biological effects of ML858 (salinosporamide A) and bortezomib Mol. Cancer Ther., December 1, 2006; 5(12): 3052 - 3061. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M.-V. Mateos, J.-M. Hernandez, M.-T. Hernandez, N.-C. Gutierrez, L. Palomera, M. Fuertes, J. Diaz-Mediavilla, J.-J. Lahuerta, J. de la Rubia, M.-J. Terol, et al. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study Blood, October 1, 2006; 108(7): 2165 - 2172. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. A. Obeng, L. M. Carlson, D. M. Gutman, W. J. Harrington Jr, K. P. Lee, and L. H. Boise Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells Blood, June 15, 2006; 107(12): 4907 - 4916. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. R. Berenson, H. H. Yang, K. Sadler, S. G. Jarutirasarn, R. A. Vescio, R. Mapes, M. Purner, S.-p. Lee, J. Wilson, B. Morrison, et al. Phase I/II Trial Assessing Bortezomib and Melphalan Combination Therapy for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma J. Clin. Oncol., February 20, 2006; 24(6): 937 - 944. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Z. Orlowski Initial Therapy of Multiple Myeloma Patients Who Are Not Candidates for Stem Cell Transplantation Hematology, January 1, 2006; 2006(1): 338 - 347. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. San Miguel, J. Blade, M. Boccadoro, J. Cavenagh, A. Glasmacher, S. Jagannath, S. Lonial, R. Z. Orlowski, P. Sonneveld, and H. Ludwig A Practical Update on the Use of Bortezomib in the Management of Multiple Myeloma Oncologist, January 1, 2006; 11(1): 51 - 61. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Saunders Overview of drug therapy for multiple myeloma Journal of Oncology Pharmacy Practice, September 1, 2005; 11(3): 83 - 100. [Abstract] [PDF]
|
|
|
|
|
|
R. Buzzeo, S. Enkemann, R. Nimmanapalli, M. Alsina, M. G. Lichtenheld, W. S. Dalton, and D. M. Beaupre Characterization of a R115777-Resistant Human Multiple Myeloma Cell Line with Cross-Resistance to PS-341 Clin. Cancer Res., August 15, 2005; 11(16): 6057 - 6064. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Dispenzieri Bortezomib for Myeloma -- Much Ado about Something N. Engl. J. Med., June 16, 2005; 352(24): 2546 - 2548. [Full Text] [PDF]
|
|
|
|
|
|
R. Z. Orlowski, P. M. Voorhees, R. A. Garcia, M. D. Hall, F. J. Kudrik, T. Allred, A. R. Johri, P. E. Jones, A. Ivanova, H. W. Van Deventer, et al. Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies Blood, April 15, 2005; 105(8): 3058 - 3065. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-H. Park, L. Liu, I.-H. Kim, J.-H. Kim, K.-R. You, and D.-G. Kim Identification of the Genes Involved in Enhanced Fenretinide-Induced Apoptosis by Parthenolide in Human Hepatoma Cells Cancer Res., April 1, 2005; 65(7): 2804 - 2814. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Ikezoe, Y. Yang, K. Bandobashi, T. Saito, S. Takemoto, H. Machida, K. Togitani, H. P. Koeffler, and H. Taguchi Oridonin, a diterpenoid purified from Rabdosia rubescens, inhibits the proliferation of cells from lymphoid malignancies in association with blockade of the NF-{kappa}B signal pathways Mol. Cancer Ther., April 1, 2005; 4(4): 578 - 586. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Chauhan, T. Hideshima, C. Mitsiades, P. Richardson, and K. C. Anderson Proteasome inhibitor therapy in multiple myeloma Mol. Cancer Ther., April 1, 2005; 4(4): 686 - 692. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Tang, Y. Li, D. Yu, A. Thomas-Tikhonenko, V. S. Spiegelman, and S. Y. Fuchs Targeting {beta}-Transducin Repeat-Containing Protein E3 Ubiquitin Ligase Augments the Effects of Antitumor Drugs on Breast Cancer Cells Cancer Res., March 1, 2005; 65(5): 1904 - 1908. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Goy, A. Younes, P. McLaughlin, B. Pro, J. E. Romaguera, F. Hagemeister, L. Fayad, N. H. Dang, F. Samaniego, M. Wang, et al. Phase II Study of Proteasome Inhibitor Bortezomib in Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma J. Clin. Oncol., February 1, 2005; 23(4): 667 - 675. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Lun, P. L. Zhang, N. Siegelmann-Danieli, T. M. Blasick, and R. E. Brown Intracellular Inhibitory Effects of Velcade Correlate with Morphoproteomic Expression of Phosphorylated-Nuclear Factor-{kappa}B and p53 in Breast Cancer Cell Lines Ann. Clin. Lab. Sci., January 1, 2005; 35(1): 15 - 24. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Lun, P. L. Zhang, P. K. Pellitteri, A. Law, T. L. Kennedy, and R. E. Brown Nuclear Factor-kappaB Pathway as a Therapeutic Target in Head and Neck Squamous Cell Carcinoma: Pharmaceutical and Molecular Validation in Human Cell Lines Using Velcade and siRNA/NF-{kappa}B. Ann. Clin. Lab. Sci., January 1, 2005; 35(3): 251 - 258. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Z. Orlowski The Ubiquitin Proteasome Pathway from Bench to Bedside Hematology, January 1, 2005; 2005(1): 220 - 225. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. W. Small, Y. Y. Shi, N. A. Edmund, S. Somasundaram, D. T. Moore, and R. Z. Orlowski Evidence That Mitogen-Activated Protein Kinase Phosphatase-1 Induction by Proteasome Inhibitors Plays an Antiapoptotic Role Mol. Pharmacol., December 1, 2004; 66(6): 1478 - 1490. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Berenson, H. Yang, R. Swift, K. Sadler, R. Vescio, J. Adams, and D. Schenkein Bortezomib in Combination with Melphalan in the Treatment of Relapsed or Refractory Multiple Myeloma: A Phase I/II Study. Blood (ASH Annual Meeting Abstracts), November 16, 2004; 104(11): 209 - 209. [Abstract]
|
|
|
|
 |
|
 A. Fribley, Q. Zeng, and C.-Y. Wang Proteasome Inhibitor PS-341 Induces Apoptosis through Induction of Endoplasmic Reticulum Stress-Reactive Oxygen Species in Head and Neck Squamous Cell Carcinoma Cells Mol. Cell. Biol., November 15, 2004; 24(22): 9695 - 9704. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Ikezoe, Y. Hisatake, T. Takeuchi, Y. Ohtsuki, Y. Yang, J. W. Said, H. Taguchi, and H. P. Koeffler HIV-1 Protease Inhibitor, Ritonavir: A Potent Inhibitor of CYP3A4, Enhanced the Anticancer Effects of Docetaxel in Androgen-Independent Prostate Cancer Cells In vitro and In vivo Cancer Res., October 15, 2004; 64(20): 7426 - 7431. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. H. Shah, D. Young, H. L. Kindler, I. Webb, B. Kleiber, J. Wright, and M. Grever Phase II Study of the Proteasome Inhibitor Bortezomib (PS-341) in Patients with Metastatic Neuroendocrine Tumors Clin. Cancer Res., September 15, 2004; 10(18): 6111 - 6118. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. A. deGraffenried, B. Chandrasekar, W. E. Friedrichs, E. Donzis, J. Silva, M. Hidalgo, J. W. Freeman, and G. R. Weiss NF-{kappa}B inhibition markedly enhances sensitivity of resistant breast cancer tumor cells to tamoxifen Ann. Onc., June 1, 2004; 15(6): 885 - 890. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X.-Y. Pei, Y. Dai, and S. Grant Synergistic Induction of Oxidative Injury and Apoptosis in Human Multiple Myeloma Cells by the Proteasome Inhibitor Bortezomib and Histone Deacetylase Inhibitors Clin. Cancer Res., June 1, 2004; 10(11): 3839 - 3852. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Zheng, G. V. Georgakis, Y. Li, A. Bharti, D. McConkey, B. B. Aggarwal, and A. Younes Induction of Cell Cycle Arrest and Apoptosis by the Proteasome Inhibitor PS-341 in Hodgkin Disease Cell Lines Is Independent of Inhibitor of Nuclear Factor-{kappa}B Mutations or Activation of the CD30, CD40, and RANK Receptors Clin. Cancer Res., May 1, 2004; 10(9): 3207 - 3215. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Barlogie, J. Shaughnessy, G. Tricot, J. Jacobson, M. Zangari, E. Anaissie, R. Walker, and J. Crowley Treatment of multiple myeloma Blood, January 1, 2004; 103(1): 20 - 32. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. M. Voorhees, E. C. Dees, B. O'Neil, and R. Z. Orlowski The Proteasome as a Target for Cancer Therapy Clin. Cancer Res., December 15, 2003; 9(17): 6316 - 6325. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. H. Yang, M. H. Ma, R. A. Vescio, and J. R. Berenson Overcoming Drug Resistance in Multiple Myeloma: The Emergence of Therapeutic Approaches to Induce Apoptosis J. Clin. Oncol., November 15, 2003; 21(22): 4239 - 4247. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
